Korro Bio (NASDAQ:KRRO – Get Free Report) had its price target decreased by investment analysts at Royal Bank of Canada from $105.00 to $95.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank of Canada’s target price indicates a potential upside of 139.54% from the company’s previous close.
Several other research firms also recently commented on KRRO. BMO Capital Markets reaffirmed an “outperform” rating and set a $120.00 price objective on shares of Korro Bio in a research note on Wednesday, May 15th. William Blair assumed coverage on Korro Bio in a research note on Wednesday. They set an “outperform” rating and a $180.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of Korro Bio in a research note on Wednesday. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $135.00.
View Our Latest Analysis on Korro Bio
Korro Bio Trading Up 9.1 %
Korro Bio (NASDAQ:KRRO – Get Free Report) last posted its earnings results on Tuesday, August 13th. The company reported ($2.43) earnings per share for the quarter, missing the consensus estimate of ($2.39) by ($0.04). As a group, analysts anticipate that Korro Bio will post -9.64 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Korro Bio
Several hedge funds have recently made changes to their positions in the business. Brown Brothers Harriman & Co. acquired a new stake in shares of Korro Bio during the second quarter worth $28,000. Atlas Venture Life Science Advisors LLC boosted its holdings in shares of Korro Bio by 1.6% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock worth $38,515,000 after purchasing an additional 17,857 shares during the last quarter. Rhumbline Advisers acquired a new stake in shares of Korro Bio during the second quarter worth $279,000. Bank of New York Mellon Corp acquired a new stake in shares of Korro Bio during the second quarter worth $649,000. Finally, Eventide Asset Management LLC acquired a new stake in shares of Korro Bio during the fourth quarter worth $26,185,000. Institutional investors and hedge funds own 13.18% of the company’s stock.
About Korro Bio
Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).
Recommended Stories
- Five stocks we like better than Korro Bio
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3 Stocks That Could Beat the September Blues
- The 3 Best Fintech Stocks to Buy Now
- Canopy Growth Stock: Can It Sustain Recent Gains?
- Using the MarketBeat Stock Split Calculator
- Serve Robotics Is Serving Up a Selling Opportunity
Receive News & Ratings for Korro Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Korro Bio and related companies with MarketBeat.com's FREE daily email newsletter.